Summary DBA/2J mice bearing a clonal isolate of the transplantable murine lymphocytic leukaemia line P388 were used to examine the effects of L-histidinol on the antitumour activity of three alkalyating agents (bis-chloroethylnitrosourea (BCNU), cis-diamminedichloroplatinum (11) (cisDDP) and cyclophosphamide) and the antitumour antibiotic daunomycin. Single, combined treatments with L-histidinol and either BCNU or cisDDP, at doses of the alkylating agents which were ineffective when used alone, were completely curative. Dose-response studies showed that L-histidinol conferred dose-dependent, synergistic improvements on the capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukemia. For combinations of L-histidinol and cyclophosphamide or daunomycin, two successive treatments with Lhistidinol and drug were required to obtain a significant portion of long-term survivors. Thus, in this model system, the L-histidinol/anticancer drug combination approach for improving experimental cancer chemotherapy can be employed successfully with three alkylating agents and the antitumour antibiotic daunomycin.
It has been argued that the adverse side-effects of anticancer drugs constitute the single most important factor in preventing their use at doses capable of curing human malignancies (Schilsky & Yarbo, 1984) . Thus, a strategy which alters the action of cancer drugs such that their life-threatening toxicity for normal tissues is reduced, while their capacity to eradicate in situ tumour cells is enhanced, should improve the efficacy of currently available antineoplastic agents. Previous investigations from this laboratory have demonstrated that L-histidinol, a structural analogue of the essential amino acid L-histidine, can modulate cancer drug toxicity in this manner. In DBA/2J mice bearing either L1210 leukaemia (Warrington et al., 1984;  Warrington & Fang, 1985; Warrington, 1986) or P815 mastocytoma (Warrington et al., 1987) , L-histidinol eliminated the bone marrow toxicity otherwise associated with the in vivo use of the agents cytosine arabinoside (araC) and 5-fluorouraicil (FUra). L-Histidinol also provided a statistically significant increase in the killing of clonogenic tumour cells, in the same animals, by these two antimetabolites. These experiments also showed that L-histidinol protected tumour-free animals from supralethal doses of FUra and that the increase in selectivity of the L-histidinol/FUra combination provided parallel increases in the survival of animals bearing L1210 leukaemia (Warrington et al., 1984) .
Recently, other workers have begun to investigate the L-histidinol/anticancer drug combination approach for improving experimental chemotherapy. For example, the studies of Edelstein and Heilbrun (1988) with L1210 leukaemia have confirmed and, in some areas, extended our earlier findings. Ridgway and Stewart (1988) demonstrated that L-histidinol offers marked improvement in the therapeutic efficacy of some conventional antitumour agents against an advanced, solid tumour form of B16 melanoma in BDF1 mice. In contrast, a different response to FUra/L-histidinol combinations was reported by Stolfi et al. (1987) . Although they showed that L-histidinol protected CD8Fl mice from FUramediated leukopenia, body weight loss and mortality, they went on to show that L-histidinol actually interfered with the capacity of FUra to eradicate the solid CD8Fl breast tumour in CD8Fl mice. Therefore, in this model, L-histidinol/FUra combinations did not confer therapeutic advantage. More recently, the same group showed that L-histidinol reduced FUra incorporation into RNA in the normal mouse tissue and in the CD8Fl breast tumour (Sawyer et al., 1988) . The authors suggested that L-histidinol is an effective modulator of FUra toxicity in those types of tumours wherein the major mode of action of FUra is to inhibit thymidylate synthetase via its metabolic conversion to 5-fluorodeoxy-uridine. The latter mode is presumed to be the case for the tumour models studied in this laboratory.
The objective of this study was to determine whether Lhistidinol would modulate the action of other classes of antineoplastic agents in the same manner as has been shown for antimetabolites. Of particular interest were the alkylating agents and the anthracycline antibiotics, which share a number of attributes, the most important of which is remarkable clinical effectiveness (Chabner & Meyers, 1983 10% (v/v) fetal bovine serum. In vivo assessments of responses of CFU-C/GM and intrafemoral P388 cells employed the previously described intrafemoral tumour model (Warrington & Fang, 1985; Warrington, 1986) . For the saline/BCNU and L-histidinol/BCNU-treated groups, each determination of intrafemoral tumour and CFU-C/GM responses required the femurs of six mice. For the L-histidinol/drug-treated and saline-treated groups, the femurs of four and two mice, respectively, were employed.
Animal survival experiments and drug treatment protocols Appropriate numbers of DBA/2J mice were injected intraperitoneally with 1 x 106 P388 leukaemia cells. For evaluations using the early treatment mode, the animals were divided randomly into treatment groups (six per group) 24 h later, and subsequently treated, as described below. For evaluations using the delayed treatment mode, the protocol was the same, except that grouping and drug treatments were instigated 72 h after the tumour cells had been injected. A standard drug treatment protocol was used in all cases, and is as follows: 24 (or 72) hours after i.p. injection of tumour cells, the animals were placed, randomly, into treatment groups of six which received saline; drug; both L-histidinol and drug (drug was given at 0 time; L-histidinol was given in five consecutive 5 mg injections at -2, 0, 2. 4, and 6 hours) or L-histidinol alone (given five times in 5 mg injections, as above). The concentrations of anticancer drug employed is shown in each legend; the L-histidinol was given as described, except where noted otherwise. Thereafter, the number of surviving animals were scored at 24-h intervals. The pooled results of two independent determinations are shown in the figures. Accumulated data for various determinations are shown in Tables I and II (Warrington & Fang, 1985; Warrington, 1986) Figure 3 shows that L-histidinol has a modest, probably additive effect on the lower doses of BCNU tested. However, as the dose of BCNU employed was increased, the relative effect of increasing doses of L-histidinol also increased. At the highest dose of BCNU tested (I mg per animal), the three concentrations of L-histidinol tested had an increasing, eventually synergistic, effect of survival time. Similar effects are evident in Figure 4 , which shows the results of an analysis of the interactions between L-histidinol and cisDDP. In this case, however, it is clear that the drug and L-histidinol are interacting in a more complex manner than was observed for BCNU and L-histidinol. For the two lower doses of cisDDP used, L-histidinol has a dose-dependent and synergistic effect on survival times. For the highest dose of Lhistidinol with the two lower cisDDP doses, the interaction was synergistic and totally curative. The highest dose of cisDDP employed did not give improved survival, presumably because of toxicity; this toxicity was partially countered only by the highest dose of L-histidinol. .)_ 0 Improved treatment with two courses of L-histidinol and either cyclophosphamide or daunomycin
Combinations of L-histidinol and either cyclophosphamide or daunomycin were also assessed by survival experiments. Although these agents were less influenced by L-histidinol than were BCNU and cisDDP, the combinations proved nevertheless to be efficacious. As is seen in Figure 5 and Table I , no long-term survivors were observed for single or double treatments with either of these drugs on their own. With both drugs, single histidinol/drug regimens gave improved 50% survival time compared to the single drug-alone treatments and, in the case of cyclophosphamide, the single combination regimen gave four of 12 long-term survivors ( Figure 5 and Table I (Table II) . With L1210 leukaemia, L-histidinol and BCNU gave five out of 12 long-term survivors at a dose of BCNU which was completely ineffective on its own (Table II) . A single course of L-histidinol and BCNU cured 100% of C57/BL mice of disseminated B16flO melanoma (Table II) at a dose of BCNU which cured three of 18 animals on its own. Thus, the combination of L-histidinol and BCNU appears to be a particularly effective combination for treating transplantable murine tumours in situ, whether these are related to P388 leukaemia or not.
Discussion Two significant observations are made in this study. The first is that L-histidinol increases the selectivity of both alkylating agents and an antitumour antibiotic in this experimental model. Figure 1 demonostrates this capacity for BCNU; the analogue eliminates the toxicity BCNU otherwise possess for the CFU-C/GM and increases the ability of the drug to eradicate P388 leukaemia cells resident in the same tissue. Similar modulations of the toxicity of cyclophosphamide, adriamycin and daunomycin mediated by co-administration of L-histidinol were observed with the intrafemoral model. The second observation, which is presumed to be a consequence of this improved selectivity, is that L-histidinol also improves the efficacy of the three alkylating agents and the antitumour antibiotic tested in the P388 leukaemia/DBA/2J mouse model. The improvement is most dramatic with BCNU and cisDDP. Combining either of these alkylating agents and L-histidinol, at levels which were completely ineffective when used alone, proved to be 100% curative for P388 leukaemia (Figures 2, 3 and 4) . Dose-response studies (Figures 3 and 4) showed that L-histidinol conferred dosedependent, synergistic improvements on the capacities of both BCNU and cisDDP to increase the life-span of DBA/2J mice bearing P388 leukaemia. Although the response was neither as dramatic nor as complete as with BCNU and cisDDP, L-histidinol nevertheless improved significantly the efficacy of another alkylating agent, cyclophosphamide, and the anthracycline daunomycin in this experimental tumour model. With these agents, two courses in combination with L-histidinol were required to obtain >50% long-term survivors ( Figure 5 and Table I ). As was the case with BCNU and cisDDP, the doses of these two drugs which proved to be curative for >50% of the animals when used in conjunction with L-histidinol gave no long-term survivors when employed alone.
Because the studies reported herein employed a clonal isolate of P388, the 'standard' P388 leukaemia line maintained by the USNCI/DTP tumour repository was obtained. After expansion in DBA/2J mice, this form of P388 leukaemia was injected into animals and challenged with BCNU and L-histidinol/BCNU combinations. This non-cloned form of P388 was less aggressive, but much more responsive to BCNU, than was its cloned counterpart, since the 50% survival time of DBA/2J mice bearing the standard P388 leukaemia was extended from 12 to 40 days with a single treatment with BCNU (1 mg per animal). However, only one out of six animals in this group became a long-term survivor. In contrast, all animals bearing the standard, animal-passaged P388 leukaemia which were treated with L-histidinol and BCNU survived (data not shown). Thus, the marked synergy between L-histidinol and BCNU observed in Figure 2 does not appear to be due to some peculiar attribute of that particular isolate. This notion is further supported by the data in Table II , which show tha other transplantable murine tumours also respond well to L-E 3tidinol and BCNU.
We have recently demonstrated that L-histidinol has the capacity to overcome the multidrug resistant phenotype in two cell lines which over-express P-glycoprotein (Warrington & Fang, 1989) . This observation, coupled with the findings reported in this paper, suggest that there are means not only of improving the therapeutic indices of commonly used antineoplastic agents, but also of overcoming the problem of multidrug resistance in experimental systems. Whether L-histidinol, or some other agent, will achieve these effects in the clinical situation remains to be demonstrated.
